Targeting HER2 for the treatment of breast cancer.

Abstract

HER2 (ErbB2), a member of the HER family of tyrosine kinase receptors (HER1-4), is a major driver of tumor growth in 20% of breast cancers. Treatment with the anti-HER2 monoclonal antibody trastuzumab has revolutionized the outcome of patients with this aggressive breast cancer subtype, but intrinsic and acquired resistance is common. Growing understanding of the biology and complexity of the HER2 signaling network and of potential resistance mechanisms has guided the development of new HER2-targeted agents. Combinations of these drugs to more completely inhibit the HER receptor layer, or combining HER2-targeted agents with agents that target downstream signaling, alternative pathways, or components of the host immune system, are being vigorously investigated in the preclinical and clinical settings. As a result, the list of more effective and well tolerated FDA-approved new regimens for patients with HER2+ tumors is constantly growing.

DOI: 10.1146/annurev-med-042513-015127
0100200300201520162017
Citations per Year

290 Citations

Semantic Scholar estimates that this publication has 290 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Rimawi2015TargetingHF, title={Targeting HER2 for the treatment of breast cancer.}, author={Mothaffar F Rimawi and Rachel Schiff and Charles Kent Osborne}, journal={Annual review of medicine}, year={2015}, volume={66}, pages={111-28} }